| Primary |
| Prophylaxis |
19.0% |
| Antibiotic Therapy |
11.6% |
| Acute Lymphocytic Leukaemia |
8.3% |
| Aspergilloma |
6.6% |
| Cardiac Failure Congestive |
6.6% |
| Bronchitis |
5.8% |
| Candidiasis |
4.1% |
| Urinary Tract Infection |
4.1% |
| Infection |
3.3% |
| Mediastinitis |
3.3% |
| Pharyngeal Abscess |
3.3% |
| Pseudomonas Infection |
3.3% |
| Pyrexia |
3.3% |
| Cystic Fibrosis |
2.5% |
| Enterocolitis Bacterial |
2.5% |
| Haemorrhage |
2.5% |
| Infection Prophylaxis |
2.5% |
| Lobar Pneumonia |
2.5% |
| Pancytopenia |
2.5% |
| Respiratory Tract Infection |
2.5% |
|
| Drug Rash With Eosinophilia And Systemic Symptoms |
18.2% |
| Coagulation Factor V Level Decreased |
9.1% |
| Agranulocytosis |
6.1% |
| Dermatitis Allergic |
6.1% |
| Drug Interaction |
6.1% |
| Liver Injury |
6.1% |
| Pneumonia |
6.1% |
| Retroperitoneal Haematoma |
6.1% |
| Acute Generalised Exanthematous Pustulosis |
3.0% |
| Acute Respiratory Distress Syndrome |
3.0% |
| Anaphylactoid Shock |
3.0% |
| Cardiac Disorder |
3.0% |
| Confusional State |
3.0% |
| Continuous Haemodiafiltration |
3.0% |
| Cytolytic Hepatitis |
3.0% |
| Dermatitis Exfoliative |
3.0% |
| Face Oedema |
3.0% |
| Febrile Neutropenia |
3.0% |
| Gamma-glutamyltransferase Increased |
3.0% |
| Grand Mal Convulsion |
3.0% |
|
| Secondary |
| Product Used For Unknown Indication |
28.0% |
| Bacteraemia |
11.8% |
| Hypertension |
10.7% |
| Sepsis |
4.9% |
| Type 2 Diabetes Mellitus |
4.0% |
| Pneumonia |
3.6% |
| Septic Shock |
3.4% |
| Antibiotic Therapy |
3.3% |
| Depression |
3.1% |
| Pain |
3.0% |
| Pancreatitis |
3.0% |
| Sedation |
2.7% |
| Acute Lymphocytic Leukaemia |
2.5% |
| Supplementation Therapy |
2.5% |
| Disease Progression |
2.4% |
| Prophylaxis |
2.4% |
| Toxic Epidermal Necrolysis |
2.4% |
| Thrombosis Prophylaxis |
2.2% |
| Bronchitis |
2.1% |
| Candidiasis |
2.1% |
|
| Toxic Epidermal Necrolysis |
26.1% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
10.2% |
| Clostridium Test Positive |
9.1% |
| Agranulocytosis |
5.7% |
| Tumour Flare |
5.7% |
| Pyrexia |
4.5% |
| Septic Shock |
4.5% |
| Pancytopenia |
3.4% |
| Skin Exfoliation |
3.4% |
| Stevens-johnson Syndrome |
3.4% |
| Urine Output Decreased |
3.4% |
| Cardiac Arrest |
2.3% |
| Continuous Haemodiafiltration |
2.3% |
| Drug Interaction |
2.3% |
| Leukocytoclastic Vasculitis |
2.3% |
| Pneumonia Fungal |
2.3% |
| Rash |
2.3% |
| Septic Embolus |
2.3% |
| Toxic Skin Eruption |
2.3% |
| Treatment Failure |
2.3% |
|
| Concomitant |
| Product Used For Unknown Indication |
15.6% |
| Drug Use For Unknown Indication |
15.1% |
| Acute Myeloid Leukaemia |
9.0% |
| Pneumonia |
7.3% |
| Prophylaxis |
6.5% |
| Infection |
5.2% |
| Atrial Fibrillation |
4.0% |
| Pyrexia |
4.0% |
| Sepsis |
3.5% |
| Hypertension |
3.4% |
| Diabetes Mellitus |
3.1% |
| Pain |
3.1% |
| Acute Lymphocytic Leukaemia |
3.0% |
| Multiple Myeloma |
3.0% |
| Cardiomyopathy |
2.6% |
| Infection Prophylaxis |
2.6% |
| Rectal Abscess |
2.4% |
| Chronic Lymphocytic Leukaemia |
2.2% |
| Oedema |
2.2% |
| Immunosuppression |
2.0% |
|
| Sepsis |
15.0% |
| Septic Shock |
11.1% |
| Multi-organ Failure |
7.2% |
| Vomiting |
7.2% |
| Cytotoxic Cardiomyopathy |
5.9% |
| Thrombocytopenia |
5.9% |
| Tumour Haemorrhage |
5.9% |
| Coma |
3.9% |
| Death |
3.9% |
| Pneumonia |
3.9% |
| Urinary Tract Infection |
3.9% |
| Asthma |
3.3% |
| Pyrexia |
3.3% |
| Renal Failure Acute |
3.3% |
| Urosepsis |
3.3% |
| Hepatotoxicity |
2.6% |
| Hypotension |
2.6% |
| Neutropenia |
2.6% |
| Rhabdomyolysis |
2.6% |
| Somnolence |
2.6% |
|
| Interacting |
| Prophylaxis |
29.6% |
| Product Used For Unknown Indication |
17.6% |
| Urinary Tract Infection |
14.8% |
| Cardiac Failure Congestive |
8.3% |
| Acute Promyelocytic Leukaemia |
3.7% |
| Angina Pectoris |
3.7% |
| Pneumonia Aspiration |
3.7% |
| Antibiotic Prophylaxis |
1.9% |
| Cardiac Failure |
1.9% |
| Coronary Artery Disease |
1.9% |
| Gastrooesophageal Reflux Disease |
1.9% |
| Hypertension |
1.9% |
| Ischaemic Heart Disease Prophylaxis |
1.9% |
| Pain |
1.9% |
| Parkinson's Disease |
1.9% |
| Pyrexia |
1.9% |
| Infection |
0.9% |
| Influenza |
0.9% |
|
| Retroperitoneal Haematoma |
46.7% |
| Drug Interaction |
26.7% |
| Hypokalaemia |
13.3% |
| Granulocytopenia |
6.7% |
| Hypovolaemic Shock |
6.7% |
|
